ReviewAdvances in delivery of Irinotecan (CPT-11) active metabolite 7-ethyl-10-hydroxycamptothecin

Add time:08/25/2019    Source:sciencedirect.com

CPT-11 is a first-line chemotherapy for advanced or metastatic colorectal cancers. 7-Ethyl-10-hydroxycamptothecin (SN38), the active metabolite of CPT-11, has an anticancer efficacy 100–1000 folds more than CPT-11 in vitro. However, the drawbacks such as ultralow solubility and poor stability, greatly limit the clinical applications of SN38. Recently, SN38-based nanomedicines have greatly improved the pharmaceutical and therapeutic characteristics of SN38. In addition, these nanosized delivery systems can target tumor tissues via the EPR effect and/or active-targeting strategies, thereby significantly improving anticancer efficacy, reducing side effects and reversing drug resistance. This review focuses on the advances of nano-delivery systems for SN38. We categorize the published studies into two groups, physical encapsulation and chemical conjugation, for the development of SN38 nano-delivery systems, and particularly summarize those for active tumor targeting. The advantages and shortcomings of current SN38 nano-delivery systems, aiming to develop more potent SN38 nano-delivery systems, are also discussed.

We also recommend Trading Suppliers and Manufacturers of ETHYL (2S)-2,3-EPOXYPROPANOATE (cas 111058-34-5). Pls Click Website Link as below: cas 111058-34-5 suppliers

Prev:Short communicationQuantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography–tandem mass spectrometry
Next:ReviewStructure and electrochemistry of proteins harboring iron-sulfur clusters of different nuclearities. Part III. [4Fe-4S], [3Fe-4S] and [2Fe-2S] iron-sulfur proteins)